Dr Andrew Chantry

Department of Oncology and Metabolism

Senior Clinical Lecturer

Consultant Haematologist

a.d.chantry@sheffield.ac.uk
+44 114 215 9003

Full contact details

Dr Andrew Chantry
Department of Oncology and Metabolism
EU22
The Medical School
Beech Hill Road
Sheffield
S10 2RX
Profile

Dr Andy Chantry is a Senior Clinical Lecturer in the Dept of Oncology, University of Sheffield and leads the Sheffield Myeloma Research Team (SMaRT). He is also an Honorary Consultant Haematologist in the Dept of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust.

Since appointment in 2012, he has been awarded over £1.5million in research grants, notably from Leukaemia and Lymphoma Research. He has also received substantial industry sponsorship and access to novel compounds from Celgene, Acceleron, Novartis and Amgen.

Research interests

His principal research interests are anabolic strategies in the treatment of myeloma bone disease and novel strategies to target myeloma tumour. He also has holistic research interests including life with cancer – holistic care and quality of life studies, computational modeling of cancer including using digital simulations and game technology.

Publications

Journal articles

Chapters

Conference proceedings papers

Teaching activities

He lectures on the undergraduate MB ChB course and informally conducts postgraduate teaching of junior doctors and haematology trainees. He is a contributor to MSc in Translational Oncology and the MSc in Health Care Studies.

Professional activities

Nationally, he is an executive member of the NCRI Myeloma Sub-Group, through which all significant UK Myeloma Clinical Trials are administered. He is also an executive member of the United Kingdom Myeloma Forum, the national body for Haematologists leading clinical and research led developments in the UK. He is a member of the UKMF National Guidelines Group with a special interest in Myeloma Bone Disease.

Locally, he is an executive member of the local Cancer Clinical Trial Executive Committee and a member of the Sheffield Experimental Cancer Medicine Centre. He is a member of the Mellanby Centre for Bone Oncology and Insigneo, the Centre for in Silico Medical Research.